Cancer giant Bristol Myers Squibb (NYSE: BMY) has secured a new European approval for its checkpoint blocker Opdivo (nivolumab), in non-small cell lung cancer (NSCLC).
The European Commission has granted marketing authorization for the aging blockbuster, together with chemotherapy, in the neoadjuvant treatment setting.
One of the pioneers of cancer immunotherapy, Bristol Myers continues to invest in Opdivo, growing its revenue base and approved indications considerably.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze